Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Date:9/9/2008

12,012,000 7,440,000

Capital lease obligation, less current

portion 16,000 22,000

Commitments and contingencies

STOCKHOLDERS' EQUITY:

Preferred stock -- $.001 par value;

authorized 5,000,000 shares; non-voting;

nil shares outstanding - -

Common stock -- $.001 par value;

authorized 325,000,000 shares;

outstanding -- 226,210,617 and 226,210,617,

respectively 226,000 226,000

Additional paid-in capital 246,476,000 246,205,000

Accumulated deficit (235,922,000) (230,836,000)

Total stockholders' equity 10,780,000 15,595,000

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $22,808,000 $23,057,000

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED

July 31, 2008 July 31, 2007

Unaudited Unaudited

REVENUES:

Contract manufacturing revenue $1,193,000 $1,621,000

Government contract revenue 324,000 -

License revenue - 4,000

Total revenues 1,517,000 1,625,000

COSTS AND EXPENSES:

Cost of contract manufacturing 903,000 1,181,000

Research and development 4,068,000 3,624,000

Selling, general and administrative 1,706,000 1,708,000

Total costs and expenses 6,677,000 6,513,000

LOSS FROM OPERATIONS (5,160,000) (4,888,000)

OTHE
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
2. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
3. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
4. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
7. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
8. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
9. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... ... designer, manufacturer and supplier, announces the launch of their 2nd generation cell therapy ... the current miniPOD CT, but it also represents a new POD® design. ...
(Date:7/29/2015)... ... July 29, 2015 , ... Brady (NYSE:BRC), a ... Label Guide . To align chemical container labeling with OSHA’s updated Hazard Communication ... label components, an example of an accurate label, and pictogram uses and meanings. ...
(Date:7/29/2015)... , July 29, 2015  Therapath Neuropathology ( ... increased partnerships with VA and Military Medical centers ... Fiber Density (ENFD) and Sweat Gland Nerve Fiber ... neuropathy ( https://therapath.com/skin ). Demonstration ... Density (ENFD) on punch skin biopsy is a ...
(Date:7/29/2015)... -- Indivior PLC (LON: INDV) today announced that the New ... and received Priority Review by the U.S. Food and ... This naloxone nasal spray comes as a pre-filled device ... the nasal mucosa. 1 The device has been ... better equipped to help an opioid overdose victim. ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Brady Announces a New GHS Label Guide 2Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... Market Research, a global provider of pharmaceutical competitive intelligence ... "Thought Leader Insight & Analysis: Alzheimer,s Disease," designed to ... with a stake in the market for diagnostics and ... ). , , MedPredict interviewed ...
... ... On-Site at Komen Western New York Race for the Cure® , ... Ottawa, ON (PRWEB) June 12, 2009 -- DNA Genotek , a ... Roswell Park Cancer Institute (RPCI) to collect DNA saliva samples on-site at the Susan ...
... ... biofuels could be entering the tanks of aircraft, according to the Geneva-based Air Transport Action ... this "new age in flight", the group this week launches a new publication, The Beginner,s ... ...
Cached Biology Technology:New MedPredict Report Reveals Top Alzheimer's Experts' Insights on Diagnostics and Treatments in Development Pipeline 2DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 2DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 3Welcome to the Biofuel Age of Flight 2Welcome to the Biofuel Age of Flight 3
(Date:6/29/2015)... June 24, 2015 Research ... the "Latin America Biomedical Sensors Market - Growth, ... The Latin America Biomedical Sensors market is ... of 2.04% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:6/25/2015)... 2015  Imagine a tool specifically designed to help ... life. That,s exactly what USANA,s True Health Assessment ... portable health program provides a personalized approached to measuring ... your lifestyle and nutrition. At the ... night, USANA,s THA was honored with the Industry Innovation ...
(Date:6/24/2015)... June 24, 2015 This report provides market ... next six years. It contains an analysis of the ... with their impact from the short, medium, and long ... the industry, market, and technology trends that currently, prevail ... of concerned authorities to efficiently manage the increasing marine ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... -- Today, oxygen takes up a hefty portion of Earth,s ... air we breathe. However, very early in Earth,s history, O2 ... in the turbulent mix of primordial gases. It wasn,t until ... when oxygen made any measurable dent in the atmosphere, stimulating ...
... salt for all seasons. It turns up not only in ... coral reefs and even in pearls. The compound exists ... it is not clear what determines which variant an organism ... A team of researchers led by LMU geobiologist Dr. Azizur ...
... at risk for a certain form of colon and other ... surviving or even avoiding the diseases, thanks to a new ... Hospital. The Intermountain Heathcare group of scientists used sophisticated ... identify patients who may have Lynch syndrome, an inherited cancer ...
Cached Biology News:MIT: Oxygen's watery past 2MIT: Oxygen's watery past 3New process that may save lives of cancer patients is effective and significantly less costly 2New process that may save lives of cancer patients is effective and significantly less costly 3